• Profile
Close

Efficacy and safety of IDeglira vs basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin; dual VII randomized clinical trial

Diabetes Care Mar 04, 2018

Billings LK, et al. - A comparative scrutiny was conducted of the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) vs basal-bolus insulin in patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20–50 units/day and metformin. Findings demonstrated that IDegLira treatment elicited HbA1c reductions that were comparable to basal-bolus, displaying statistically superior lower hypoglycemia rates and weight loss vs weight gain in the study cohort.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay